Privo Technologies is a biotechnology company dedicated to improving the standard of care for cancer patients. Their groundbreaking products, PRV111 and PRV211, have the potential to revolutionize cancer treatment. PRV111 is a nanoengineered polymeric patch embedded with cisplatin nanoparticles, capable of treating over half of all solid tumor cancers.

By delivering potent anticancer drugs directly to the tumor site, PRV111 improves drug efficacy and safety while reducing toxic side effects. This innovative approach eliminates the need for needles and minimizes the impact of stomach acids, ultimately improving patient outcomes and compliance. PRV211 is a sterilized, rapid release chemotherapy patch that can be applied post-tumor resection to reduce the risk of cancer recurrence.

Privo Technologies' cutting-edge platform has broad applications in other mucosal cancers as well. The company has received significant recognition, including $18 million in non-dilutive funding and a $2 million grant from the FDA for their clinical trials. Privo Technologies is committed to advancing cancer treatment and making a lasting impact on patient lives.

Contact them today to learn more